Smith & Nephew Analyst Price Targets

Smith & Nephew PLC

SNNNYSE

Trade with Public

$29.06

-0.03-0.1%

마지막 업데이트: Oct 19, 5:49 AM

$29.06

-0.03-0.1%

개요 뉴스 실적 전망 이벤트목표가재무 심리 지분 현황 배당금 비교 옵션 주식 보고서

Smith & Nephew Analyst Price Targets

Wall Street analyst price targets and consensus rating for Smith & Nephew (SNN).

Price Target Range — 6 Quarters

Analyst Consensus — 6 Analysts

5Hold

1Sell

Consensus RatingHold# Analysts6Avg. Consensus PT$32Upside to Avg. PT+8.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 31, 2026	BTIG	Ryan Zimmerman	Initiate	Neutral	—
Aug 6, 2026	JP Morgan	David Adlington	Downgrade	Overweight→Neutral	—
Aug 5, 2026	Barclays	Hassan Al-Wakeel	Downgrade	Equal-Weight→Underweight	—
May 11, 2026	Canaccord Genuity	Caitlin Cronin	PT Cut	Hold	$32→$30
Mar 5, 2026	Canaccord Genuity	Caitlin Cronin	PT Raise	Hold	$34→$35
Nov 11, 2025	Canaccord Genuity	Caitlin Cronin	PT Cut	Hold	$36→$34
Oct 14, 2025	Bernstein	Lisa Clive	Downgrade	Outperform→Market Perform	$38
Aug 18, 2025	Canaccord Genuity	Caitlin Cronin	PT Raise	Hold	$28→$36
May 1, 2025	Canaccord Genuity	Caitlin Cronin	PT Raise	Hold	$27→$28
Mar 17, 2025	Canaccord Genuity	Caitlin Cronin	Maintained	Hold	$27
Mar 12, 2025	UBS	Graham Doyle	Downgrade	Buy→Neutral	—
Feb 26, 2025	Canaccord Genuity	Kyle Rose	Maintained	Hold	$27
Jun 5, 2024	UBS	Graham Doyle	Upgrade	Neutral→Buy	—

More with Benzinga EdgeGet Access

Analyst Ratings News

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

Analyst ratings and news for high-yield healthcare stocks Medtronic (3.06%), Smith & Nephew (2.74%) and GSK (3.65%).

Avi Kapoor

This Lumentum Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Evercore ISI

Avi Kapoor

PRO
BTIG Initiates Coverage On Smith & Nephew with Neutral Rating

BTIG analyst Ryan Zimmerman initiates coverage on Smith & Nephew (NYSE:SNN) with a Neutral rating.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Hold on Smith & Nephew, Lowers Price Target to $30

Canaccord Genuity analyst Caitlin Cronin maintains Smith & Nephew (NYSE:SNN) with a Hold and lowers the price target from $32 to $30.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Hold on Smith & Nephew, Lowers Price Target to $34

Canaccord Genuity analyst Caitlin Cronin maintains Smith & Nephew (NYSE:SNN) with a Hold and lowers the price target from $36 to $34.

Benzinga Newsdesk

PRO
Bernstein Downgrades Smith & Nephew to Market Perform, Announces $37.5 Price Target

Bernstein analyst Lisa Clive downgrades Smith & Nephew (NYSE:SNN) from Outperform to Market Perform and announces $37.5 price target.

Benzinga Newsdesk

Smith & Nephew PLC

Smith & Nephew Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

This Lumentum Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

PRO
BTIG Initiates Coverage On Smith & Nephew with Neutral Rating

PRO
Canaccord Genuity Maintains Hold on Smith & Nephew, Lowers Price Target to $30

PRO
Canaccord Genuity Maintains Hold on Smith & Nephew, Lowers Price Target to $34

PRO
Bernstein Downgrades Smith & Nephew to Market Perform, Announces $37.5 Price Target

뉴스

파트너 / 기고자

벤징가 글로벌

Smith & Nephew Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

This Lumentum Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

PRO
BTIG Initiates Coverage On Smith & Nephew with Neutral Rating

PRO
Canaccord Genuity Maintains Hold on Smith & Nephew, Lowers Price Target to $30

PRO
Canaccord Genuity Maintains Hold on Smith & Nephew, Lowers Price Target to $34

PRO
Bernstein Downgrades Smith & Nephew to Market Perform, Announces $37.5 Price Target

People Also Watch

People Also Watch

Smith & Nephew PLC

Smith & Nephew Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

This Lumentum Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

PROBTIG Initiates Coverage On Smith & Nephew with Neutral Rating

PROCanaccord Genuity Maintains Hold on Smith & Nephew, Lowers Price Target to $30

PROCanaccord Genuity Maintains Hold on Smith & Nephew, Lowers Price Target to $34

PROBernstein Downgrades Smith & Nephew to Market Perform, Announces $37.5 Price Target

뉴스

파트너 / 기고자

벤징가 글로벌

Smith & Nephew Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

This Lumentum Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

PROBTIG Initiates Coverage On Smith & Nephew with Neutral Rating

PROCanaccord Genuity Maintains Hold on Smith & Nephew, Lowers Price Target to $30

PROCanaccord Genuity Maintains Hold on Smith & Nephew, Lowers Price Target to $34

PROBernstein Downgrades Smith & Nephew to Market Perform, Announces $37.5 Price Target

People Also Watch

People Also Watch

PRO
BTIG Initiates Coverage On Smith & Nephew with Neutral Rating

PRO
Canaccord Genuity Maintains Hold on Smith & Nephew, Lowers Price Target to $30

PRO
Canaccord Genuity Maintains Hold on Smith & Nephew, Lowers Price Target to $34

PRO
Bernstein Downgrades Smith & Nephew to Market Perform, Announces $37.5 Price Target

PRO
BTIG Initiates Coverage On Smith & Nephew with Neutral Rating

PRO
Canaccord Genuity Maintains Hold on Smith & Nephew, Lowers Price Target to $30

PRO
Canaccord Genuity Maintains Hold on Smith & Nephew, Lowers Price Target to $34

PRO
Bernstein Downgrades Smith & Nephew to Market Perform, Announces $37.5 Price Target